atezolizumab,cabozantinib
roche
['kcsm,(-skcsm)', 'contact-03', 'rcc,(-irccs),(-srcc),(-urcc)', 'renal,(-adrenal)']
immune checkpoint inhibitor rechallenge did not improve outcomes in patients with advanced renal cell carcinoma in the phase 3 contact-03 trial. presented at asco 2023. #asco23 #rcc #kcsm 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.